Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry.
about
An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples.Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.Ovarian cancer: diagnostic, biological and prognostic aspects.Ovarian carcinoma diagnosis: the clinical impact of 15 years of change.High-grade serous carcinoma of tubo-ovarian origin: recent developments.Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapyDose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.Efficient molecular subtype classification of high-grade serous ovarian cancer.Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells.The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.The diagnostic role of PTEN and ARID1A in serous effusions.Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.Origin of clear cell carcinoma: nature or nurture?A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis.Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics.
P2860
Q27313766-FFBB07E3-4490-4D7D-8E49-89396FC17DE4Q33574500-652DCBCD-B691-4DCB-9A13-E8DDE52AF973Q35759295-9851497A-1203-4144-A11A-47D1ECA513BCQ35921404-D0E02B7E-B617-4860-ACF5-89D0846AC62AQ36157106-9C12DB0F-68B6-44C3-8525-67B8583A2CFAQ36416465-91E7BA72-96CA-48D7-9B26-931A7A754287Q37234793-6CDED2F5-369D-4B19-A46D-F18DEB0AE370Q37729055-50F3C487-5092-4323-82AE-08C43726B669Q38261795-004863F2-6420-46F3-B436-2DB9309B7FFBQ38378337-918E34A8-F63A-47F2-8169-C62502800A1BQ38687061-0A1F5ADF-A864-4907-888D-7349F05E2AA4Q39105227-398C6BF4-A3AE-4D05-AD1D-2F0659BE981CQ40073731-2600C0F4-8F2C-43DF-A0DE-2260CB5A049CQ42380793-DFFAB871-D132-4E57-B417-30F0CED6E852Q43924266-14C7DB83-A5DF-49D9-82DE-814298A26001Q46138773-7AB47349-AE8E-461B-B355-3A1BBCE2B512Q46364204-C498AFFA-F494-4865-92BA-EE9D974E96A5Q46837899-21001CB1-4592-4D07-87CC-05AF886CA042Q47132013-6C7C7D9A-1AED-4CBE-8FEB-8440D4209EE4Q47369086-E05151CD-E6F8-4DCA-84D3-8A2EE584E987Q48110433-D30EB304-28A2-4CC5-9EE4-0197D4DDC6D1Q48233176-7232FE5C-2D03-4F9E-A4D9-62F1F8BB0CDDQ51744236-33CA2DC1-60EE-449C-946D-FBC5343DC63FQ52675313-B51A01C5-052A-46B6-8EF0-4400CDF144BDQ55214019-9D102E0D-F19A-44A5-A2F3-F22CA97CABEEQ55256135-B4B099D6-BCC8-4D36-8F25-4112F59ABC3C
P2860
Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Ovarian carcinoma histotype de ...... e use of immunohistochemistry.
@en
type
label
Ovarian carcinoma histotype de ...... e use of immunohistochemistry.
@en
prefLabel
Ovarian carcinoma histotype de ...... e use of immunohistochemistry.
@en
P2093
P2860
P356
P1433
P1476
Ovarian carcinoma histotype de ...... he use of immunohistochemistry
@en
P2093
Anna Måsbäck
Anne-Marie Levin Jakobsen
Anni Grove
Björn I Bertelsen
C Blake Gilks
Estrid S Hansen
Marianne Lidang
Olli Carpen
P2860
P304
P356
10.1111/HIS.12349
P577
2014-03-07T00:00:00Z